Burning Rock ADS Ratio
Change
GUANGZHOU, China, May 9,
2024-Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the
"Company" or "Burning Rock"), a company focused on the application
of next generation sequencing (NGS) technology in the field of
precision oncology, today provides further details for UK ADS
holders regarding the Company's upcoming ADS Ratio Change.
On April 26, 2024, the Company
announced an upcoming change to the ratio of its American
depositary shares (the "ADSs") to Class A ordinary shares from one
(1) ADS representing one (1) Class A ordinary share to one (1) ADS
representing ten (10) Class A ordinary shares (the "ADS Ratio
Change"). The ADS Ratio Change is expected to become effective on
or about May 15, 2024 (the "Effective Date").
On the Effective Date, the ADSs are
expected to be tradeable on the Main Market of the London Stock
Exchange under the following new security codes:
|
New ADS
ISIN
|
US12233L2060
|
|
New ADS
SEDOL
|
BQ66DK4
|
To effect the ADS Ratio Change, on
the Effective Date the Company will sign Amendment No. 1 to the
Deposit Agreement dated as of June 16, 2020 ("Amendment No. 1"), by
and among the Company, Citibank, N.A., (the "Depositary") and all
holders and beneficial owners of ADSs issued thereunder.
The Form of Amendment No. 1 is
available for inspection on the website of the U.S. Securities and
Exchange Commission at:
https://www.sec.gov/Archives/edgar/data/1472033/000119380524000563/e663523_ex99-ai.htm
The Form of Amendment No. 1 has also
been submitted to the National Storage Mechanism and will shortly
be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism
Neither this announcement nor the
information contained herein, nor its publication, constitutes an
offer or solicitation by the Company, or any other issuer or entity
for the purchase or sale of any ADSs or any security relating
thereto nor does it constitute an offer, solicitation or
publication to any person in any jurisdiction where such
solicitation or publication would be unlawful.
About Burning Rock
Burning Rock Biotech Limited
(NASDAQ: BNR and LSE: BNR), whose mission is to guard life via
science, focuses on the application of next generation sequencing
(NGS) technology in the field of precision oncology. Its business
consists of i) NGS-based therapy selection testing for late-stage
cancer patients, and ii) cancer early detection, which has moved
beyond proof-of-concept R&D into the clinical validation
stage.
For more information about Burning
Rock, please visit: ir.brbiotech.com.
Safe Harbor Statement
This press release contains
forward-looking statements. These statements constitute
"forward-looking" statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and as defined in
the U.S. Private Securities Litigation Reform Act of 1995. These
forward-looking statements can be identified by terminology such as
"will," "expects," "anticipates," "future," "intends," "plans,"
"believes," "estimates," "target," "confident" and similar
statements. Burning Rock may also make written or oral
forward-looking statements in its periodic reports to the SEC, in
its annual report to shareholders, in press releases and other
written materials and in oral statements made by its officers,
directors or employees to third parties. Statements that are not
historical facts, including statements about Burning Rock's beliefs
and expectations, are forward-looking statements. Such statements
are based upon management's current expectations and current market
and operating conditions, and relate to events that involve known
or unknown risks, uncertainties and other factors, all of which are
difficult to predict and many of which are beyond Burning Rock's
control. Forward-looking statements involve risks, uncertainties
and other factors that could cause actual results to differ
materially from those contained in any such statements. All
information provided in this press release is as of the date of
this press release, and Burning Rock does not undertake any
obligation to update any forward-looking statement as a result of
new information, future events or otherwise, except as required
under applicable law.
Contact: IR@brbiotech.com
